Search results
Results from the WOW.Com Content Network
Phenylbiguanide (PBG) is a 5-HT3 agonist used to study the role of 5-HT3 receptors in the central nervous system. [1] It has been found to trigger dopamine release in the nucleus accumbens of rats. [ 2 ]
The 5-HT 3 receptor is expressed throughout the central and peripheral nervous systems and mediates a variety of physiological functions. [14] On a cellular level, it has been shown that postsynaptic 5-HT 3 receptors mediate fast excitatory synaptic transmission in rat neocortical interneurons, amygdala, and hippocampus, and in ferret visual ...
The 5-HT 3 receptor antagonists suppress vomiting and nausea by inhibiting serotonin binding to the 5-HT 3 receptors. The highest concentration of 5-HT 3 receptors in the central nervous system are found in the STN and chemoreceptor trigger zone (CTZ), and 5-HT 3 antagonists may also suppress vomiting and nausea by acting at these sites. [29]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
The pharmaceutical industry in Pakistan was estimated to be worth Rs. 748 billion (US$2.6 billion) in 2023, representing about 1% of the country's GDP. [1] The industry is largely import-dependent, with more than 90% of raw material being imported and only 12% of active pharmaceutical ingredients locally produced. [1]
Pages in category "5-HT 3 antagonists" The following 34 pages are in this category, out of 34 total. This list may not reflect recent changes. 0–9. 5-HT3 antagonist; A.
Batanopride (BMY-25,801) is an antiemetic drug of the benzamide class which acts as a selective 5-HT 3 receptor antagonist. [1] It was trialled to reduce nausea during cancer chemotherapy, but was never approved for medical use due to dose-limiting side effects including hypotension and long QT syndrome.
Alosetron, sold under the brand name Lotronex among others, is a 5-HT 3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in females only. It was patented in 1987 and approved for medical use in 2002. [2] It is currently marketed by Prometheus Laboratories Inc. .